F2G’s attempt to end a two-decade drought in novel therapies for invasive fungal infections has hit a hurdle after the FDA said it was unable to approve its olorofim candidate. The US regulator ...
UK biotech F2G has raised $100 million as it prepares to refile its olorofim candidate for invasive fungal infections, which was turned down last year by the FDA. The Manchester-based company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback